It was reported that the procedure on 10/08/2020 was to treat the 100% stenosed left proximal superficial femoral artery (sfa).As an introducer sheath was not used, slight resistance was felt during deployment of the 5.5x200 supera self-expanding stent (ses) and the stent moved a little bit forward with the proximal part of the stent ending in the common femoral artery.A control injection confirmed a good flow.On (b)(6) 2020 the patient experienced a hemorrhagic stroke, confirmed with cerebral ct scan.The supera stent was confirmed to be patent.Medication was administered and the patient remained hospitalized.The patient was discharged on (b)(6) 2020.Per the physician, the stroke was not related to the supera stent.No additional information was provided.
|
The device was not returned for evaluation.A review of the lot history record identified no manufacturing nonconformities issued to the reported lot that would have contributed to this event.Additionally, a review of the complaint history revealed no other similar complaints.It should be noted that the supera instruction for use (ifu) states: using standard technique, gain access at an appropriate anatomical site utilizing an appropriately sized introducer sheath.In this case, it could not be determined if using the supera without the use of an introducer sheath caused or contributed to the difficulties.Based on the information provided, a definitive cause for the difficulties could not be determined.It may be possible that delivering and deploying the supera stent without the use of an introducer sheath contributed to the slight resistance noted during deployment and causing the stent to slightly move forward during deployment; however, this could not be confirmed.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.Na.
|